<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>STUDY OBJECTIVE: To determine the impact of primary prophylactic colony-stimulating factor (CSF) use on febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in a large patient population receiving contemporary chemotherapy regimens to treat <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, or <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Retrospective claims analysis </plain></SENT>
<SENT sid="2" pm="."><plain>DATA SOURCES: The Surveillance, Epidemiology, and End Results (SEER)-Puget Sound <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registry and insurance claims records </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS: A total of 2728 patients aged 25Â years or older who received a diagnosis of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (998 patients), <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (688 patients), or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> (1042 patients) between January 1, 2002, and December 31, 2005, and received chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>MEASUREMENTS AND MAIN RESULTS: Initial chemotherapy regimen, CSF use (filgrastim or pegfilgrastim), and febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> events were evaluated after the first chemotherapy administration </plain></SENT>
<SENT sid="5" pm="."><plain>Subsequently, febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> rates in patients receiving primary prophylactic CSF were compared with febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> rates in patients receiving CSF in settings other than primary prophylaxis or not at <z:hpo ids='HP_0000001'>all</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The impact of primary prophylactic CSF could not be assessed for patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> because only 1 and 18 febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> events, respectively, occurred in those receiving primary prophylactic CSF </plain></SENT>
<SENT sid="7" pm="."><plain>Of the 998 patients with <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, 72 (7.2%) experienced febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, 28 of whom received primary prophylactic CSF </plain></SENT>
<SENT sid="8" pm="."><plain>In the patients with <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, we observed that primary prophylactic CSF use was associated with reduced febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> rates; however, the analysis may have been confounded by unmeasured factors associated with febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The impact of primary prophylactic CSFs on febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> rates could not be demonstrated </plain></SENT>
<SENT sid="10" pm="."><plain>Given the substantive cost of CSFs to pharmacy budgets, there are numerous opportunities for pharmacists to optimize CSF use </plain></SENT>
<SENT sid="11" pm="."><plain>Research studies are needed to evaluate if guideline-directed prescribing of primary prophylactic CSFs can improve clinical outcomes </plain></SENT>
</text></document>